Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase-2, Multi-centre, Prospective, Randomized, Standard-of-care Plus Placebo-controlled, Patient and Central Evaluator Blinded, Parallel Arm, Clinical Study to Evaluate Safety, Tolerability and Efficacy of the AUP1602-C as Treatment for Non-healing Neuro-ischemic DFU

NCT06111183 is registered in ClinicalTrials.gov with Aurealis Oy as lead sponsor.

NCT NCT06111183
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06111183 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase-2, Multi-centre, Prospective, Randomized, Standard-of-care Plus Placebo-controlled, Patient and Central Evaluator Blinded, Parallel Arm, Clinical Study to Evaluate Safety, Tolerability and Efficacy of the AUP1602-C as Treatment for Non-healing Neuro-ischemic DFU
Lead sponsor
Aurealis Oy
Phase
Phase 2
Overall status
Completed
Start date
July 21, 2023
Completion date
November 28, 2025
Enrollment
64 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic foot ulcer